- argenx floated on Euronext Brussels with an initial market capitalisation of €132m
- Proceeds of the IPO will be used to advance the clinical development of differentiated therapeutic antibody candidates
- Kempen & Co acted as Joint Global Coordinator and Joint Bookrunner and placed the majority of shares with long only specialist investors
The investment services and investment institutions mentioned on the website may not be available in your jurisdiction or to anyone other than professional investors. More information about the countries where these investment institutions are registered and the persons to whom they may be offered can be found on the website.